Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for Early-Stage Anal Cancer
NCT06493019Phase 2Recruiting
- Sponsor
- Dustin Deming
- Start
- Sep 2024
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in anal cancer, sponsored by Dustin Deming. Primary endpoint: Clinical Complete Response Rate at 6 months. Started Sep 2024; status: recruiting.
02
Drugs
03
Conditions
anal cancer
Beyond the preview
Go deeper on NCT06493019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06493019.